SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP is investigating potential violations of federal and state securities laws by certain officers and directors of the following companies: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Integral Ad Science Holding Corp. (NASDAQ: IAS), Manhattan Associates, Inc. (NASDAQ: MANH), and Crocs, Inc. (NASDAQ: CROX).
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
Johnson Fistel, PLLP is investigating claims on behalf of Regeneron Pharmaceuticals, Inc. against certain of its officers and directors.
If you are a current, long-term shareholder of Regeneron, continuously holding shares since November 2, 2023, you may have standing to hold the Company harmless from the alleged harm caused by the Company’s officers and directors by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action: https://www.johnsonfistel.com/investigations/regeneron-pharmaceuticals-inc
Previously, a class action complaint was filed against the Company. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card; (2) that these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) that, as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (4) that, because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron’s price concessions provided a competitive advantage; (5) that, as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) that, by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Integral Ad Science Holding Corp. (NASDAQ: IAS)
Johnson Fistel, PLLP is investigating potential claims on behalf of Integral Ad Science investors. Shareholders who have continuously owned IAS stock since March 3, 2023, may have standing to hold company officers and directors personally accountable for alleged misconduct and help implement corporate governance reforms. To join the IAS investigation, visit: https://www.johnsonfistel.com/investigations/integral-ad-science-holding-corp
Recently, a shareholder class action complaint was filed against the Company alleging that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges that during the Class Period, Defendants misrepresented and/or failed to disclose (i) that IAS was experiencing a new material trend of increased competitive pricing pressures and that, as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (ii) that IAS’s pricing function was no longer ‘favorable’ and IAS could not sustain its pricing and drive price increases; (iii) that pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; (iv) that the risk that competition ‘could result in increased pricing pressure’ or ‘could put pressure on us to change our prices’ had in fact transpired; and (v) as a result, the IAS’s public statements were materially false and misleading at all relevant times.
Manhattan Associates, Inc. (NASDAQ: MANH)
Johnson Fistel, PLLP is reviewing potential legal claims on behalf of Manhattan Associates, Inc. shareholders. If you have continuously held MANH shares since before October 22, 2024, you may have legal rights. To participate, visit: https://www.johnsonfistel.com/investigations/manhattan-associates-inc-2
Recently, a shareholder class action complaint was filed against the Company alleging that, throughout the Class Period, Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Manhattan Associates’ forecasting ability for its professional services; notably, the Company was either not truly equipped to deliver “responsible targets” for growth or, otherwise, Manhattan Associates’ services were not equipped to achieve such targets. Finally, the Complaint alleges that such statements absent these material facts caused Plaintiff and other shareholders to purchase Manhattan Associates’ securities at artificially inflated prices.
Crocs, Inc. (NASDAQ: CROX)
Johnson Fistel, PLLP is investigating potential claims against certain officers and directors of Crocs, Inc. If you are a long-term shareholder of CROX stock, you may be eligible to seek compensation and corporate governance changes. To join this action, visit: https://www.johnsonfistel.com/investigations/crocs-inc
Recently, a shareholder class action complaint was filed against the Company alleging that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, the Complaint alleges Defendants misrepresented and/or failed to disclose: (1) the nature and sustainability of HEYDUDE’s revenue growth by concealing that 2022 revenue growth was driven, in large part, by the Company’s efforts to stock third-party wholesalers and retailers following the February 2022 acquisition of HEYDUDE; (2) that as the Company’s retail partners began to destock this excess inventory, waning product demand further negatively impacted the Company’s financial results; and (3) that, as a result, Defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
About Johnson Fistel, PLLP
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Colorado, and Idaho. The firm represents institutional and individual investors in shareholder derivative and securities class action lawsuits. To learn more about the firm and its attorneys, visit www.johnsonfistel.com.
Recognition & Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, recovering approximately $90.7 million for clients as lead or co-lead counsel. This marks the eighth year the firm has earned this distinction based on total recoveries.
Attorney Advertising
Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication. Attorney responsible: Frank J. Johnson.
Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com
